T1	PROC 45 96	Estudio fase 3b de simplificación, de un solo brazo
T2	PROC 102 109	terapia
#1	AnnotatorNotes T2	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T3	CHEM 127 130	3TC
#2	AnnotatorNotes T3	C0209738; lamivudine; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T4	CHEM 150 161	Raltegravir
#3	AnnotatorNotes T4	C1871526; raltegravir; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T5	DISO 191 214	infectados por el VIH-1
#4	AnnotatorNotes T5	C2363741; HIV-1 infection; Disease or Syndrome
T6	DISO 256 265	molestias
#5	AnnotatorNotes T6	C2364135; Discomfort; Sign or Symptom
T7	DISO 267 276	toxicidad
#6	AnnotatorNotes T7	C0600688; Toxic effect; Injury or Poisoning
T8	DISO 305 319	comorbilidades
#7	AnnotatorNotes T8	C1275743; Co-morbid conditions; Finding
T9	DISO 341 366	interacciones de fármacos
#8	AnnotatorNotes T9	C0687133; Drug Interactions; Pathologic Function
T10	PROC 513 524	tratamiento
#9	AnnotatorNotes T10	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T11	DISO 566 619	infectados por Virus de la Inmunodeficiencia Humana-1
T12	DISO 662 671	molestias
#10	AnnotatorNotes T12	C2364135; Discomfort; Sign or Symptom
T13	DISO 673 682	toxicidad
#11	AnnotatorNotes T13	C0600688; Toxic effect; Injury or Poisoning
T14	DISO 711 725	comorbilidades
#12	AnnotatorNotes T14	C1275743; Co-morbid conditions; Finding
T15	DISO 738 763	interacciones de fármacos
#13	AnnotatorNotes T15	C0687133; Drug Interactions; Pathologic Function
T16	PROC 934 952	prueba de embarazo
#14	AnnotatorNotes T16	C0032976; Pregnancy Tests; Diagnostic Procedure
T17	PROC 997 1015	asignación al azar
T18	PROC 1096 1107	diagnóstico
#15	AnnotatorNotes T18	C0011900; Diagnosis; Diagnostic Procedure
T19	DISO 1168 1177	toxicidad
#16	AnnotatorNotes T19	C0600688; Toxic effect; Injury or Poisoning
T20	DISO 1203 1217	comorbilidades
#17	AnnotatorNotes T20	C1275743; Co-morbid conditions; Finding
T21	PROC 1432 1456	consentimiento informado
#18	AnnotatorNotes T21	C0567423; Informed consent for procedure; Therapeutic or Preventive Procedure
T22	CHEM 1718 1721	FTC
#19	AnnotatorNotes T22	C0909839; emtricitabine; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T23	CHEM 1636 1663	inhibidores de la integrasa
#20	AnnotatorNotes T23	C0376601; Integrase Inhibitors; Biologically Active Substance · Pharmacologic Substance
T24	CHEM 1712 1715	3TC
#21	AnnotatorNotes T24	C0209738; lamivudine; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T25	CHEM 1754 1757	3TC
#22	AnnotatorNotes T25	C0209738; lamivudine; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T26	CHEM 1760 1782	inhibidor de integrasa
#23	AnnotatorNotes T26	C0376601; Integrase Inhibitors; Biologically Active Substance · Pharmacologic Substance
T27	DISO 1860 1870	enfermedad
#24	AnnotatorNotes T27	C0012634; Disease; Disease or Syndrome
T28	DISO 1888 1898	enfermedad
#25	AnnotatorNotes T28	C0012634; Disease; Disease or Syndrome
T29	PROC 2012 2023	tratamiento
#26	AnnotatorNotes T29	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T30	DISO 2041 2060	Hepatitis B crónica
#27	AnnotatorNotes T30	C0524909; Hepatitis B, Chronic; Disease or Syndrome
T31	CHEM 358 366	fármacos
#28	AnnotatorNotes T31	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T32	PROC 374 381	régimen
#29	AnnotatorNotes T32	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T33	DISO 454 492	virus de la inmunodeficiencia humana-1
T34	LIVB 1066 1071	VIH-1
#30	AnnotatorNotes T34	C0019704; HIV-1; Virus
T35	CHEM 755 763	fármacos
#31	AnnotatorNotes T35	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T36	PROC 771 778	régimen
#32	AnnotatorNotes T36	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T37	DISO 1230 1258	interacciones medicamentosas
T38	PROC 1266 1273	régimen
#33	AnnotatorNotes T38	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T39	PROC 1370 1381	carga viral
#34	AnnotatorNotes T39	C1261478; Viral load measurement; Laboratory Procedure
T40	PROC 1615 1622	régimen
#35	AnnotatorNotes T40	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T41	PROC 1691 1698	régimen
#36	AnnotatorNotes T41	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T42	DISO 1726 1751	Mutaciones de resistencia
T43	PROC 1793 1814	prueba de resistencia
#37	AnnotatorNotes T43	C2049879; infectious agent phenotype nucleic acid HIV 1 drug resistance tissue culture analysis; Laboratory Procedure
T44	Date 13 17	2017
T45	Dose 132 138	300 mg
T46	Frequency 142 144	QD
T47	Dose 163 170	1200 mg
T48	Frequency 174 176	QD
T49	LIVB 181 190	pacientes
#38	AnnotatorNotes T49	C0030705; Patients; Patient or Disabled Group
T51	Spec_cue 331 340	riesgo de
T52	Date 382 388	actual
T53	LIVB 428 437	Pacientes
#39	AnnotatorNotes T53	C0030705; Patients; Patient or Disabled Group
T55	Date 525 531	actual
T56	LIVB 556 565	Pacientes
#40	AnnotatorNotes T56	C0030705; Patients; Patient or Disabled Group
T57	LIVB 581 619	Virus de la Inmunodeficiencia Humana-1
#41	AnnotatorNotes T57	C0019704; HIV-1; Virus
T59	Spec_cue 728 737	riesgo de
T60	Date 779 785	actual
T61	LIVB 818 827	pacientes
#42	AnnotatorNotes T61	C0030705; Patients; Patient or Disabled Group
T62	LIVB 844 851	hombres
#43	AnnotatorNotes T62	C0025266; Male population group; Population Group
T63	LIVB 854 861	mujeres
#44	AnnotatorNotes T63	C0043210; Woman; Population Group
T64	Age 865 881	al menos 18 años
T65	LIVB 895 917	mujeres en edad fértil
#45	AnnotatorNotes T65	C4324275; Woman of childbearing potential; Population Group
T66	Neg_cue 953 961	negativa
T67	Duration 972 983	los 10 días
T68	LIVB 1034 1043	Pacientes
#46	AnnotatorNotes T68	C0030705; Patients; Patient or Disabled Group
T69	LIVB 1125 1134	pacientes
#47	AnnotatorNotes T69	C0030705; Patients; Patient or Disabled Group
T71	Spec_cue 1220 1229	riesgo de
T73	Date 1274 1280	actual
T74	LIVB 1284 1293	Pacientes
#48	AnnotatorNotes T74	C0030705; Patients; Patient or Disabled Group
T75	Duration 1329 1346	al menos 12 meses
T76	LIVB 1403 1412	Pacientes
#49	AnnotatorNotes T76	C0030705; Patients; Patient or Disabled Group
T77	PHYS 1516 1524	Embarazo
#50	AnnotatorNotes T77	C0032961; Pregnancy; Organism Function
T78	PHYS 1526 1535	lactancia
#51	AnnotatorNotes T78	C0006147; Breast Feeding; Organism Function | C0022925; Lactation; Organ or Tissue Function
T79	PHYS 1538 1546	embarazo
#52	AnnotatorNotes T79	C0032961; Pregnancy; Organism Function
T82	LIVB 1917 1929	investigador
#53	AnnotatorNotes T82	C0035173; Research Personnel; Professional or Occupational Group
T84	LIVB 2028 2036	paciente
#54	AnnotatorNotes T84	C0030705; Patients; Patient or Disabled Group
T85	Duration 2053 2060	crónica
#55	AnnotatorNotes T85	C0205191; chronic; Temporal Concept
T87	PHYS 944 952	embarazo
#56	AnnotatorNotes T87	C0032961; Pregnancy; Organism Function
T50	Age 906 917	edad fértil
T54	LIVB 1376 1381	viral
#57	AnnotatorNotes T54	C0042776; Virus; Virus
T58	LIVB 209 214	VIH-1
#58	AnnotatorNotes T58	C0019704; HIV-1; Virus
A1	Assertion T9 Speculated
A2	Assertion T15 Speculated
A3	Population_data T65 Age
A4	Assertion T87 Negated
A5	Assertion T37 Speculated
A6	Status T40 History_of
A7	Status T23 History_of
A8	Status T41 History_of
A9	Status T24 History_of
A10	Status T22 History_of
A11	Status T43 History_of
A12	Status T28 History_of
#59	AnnotatorNotes T52	C0521116; Current (present time); Temporal Concept 
#60	AnnotatorNotes T55	C0521116; Current (present time); Temporal Concept 
#61	AnnotatorNotes T60	C0521116; Current (present time); Temporal Concept 
#62	AnnotatorNotes T73	C0521116; Current (present time); Temporal Concept 
#63	AnnotatorNotes T17	C0034656; Randomization; Research Activity
#64	AnnotatorNotes T11	C2363741; HIV-1 infection; Disease or Syndrome
#65	AnnotatorNotes T33	C2363741; HIV-1 infection; Disease or Syndrome
#66	AnnotatorNotes T1	C2826346; Single Group Study; Research Activity (?) + C1706097; Trial Phase 3B; Research Activity
#67	AnnotatorNotes T37	C0687133; Drug Interactions; Pathologic Function
T70	Spec_cue 1931 1936	pueda
T72	Observation 1937 1961	confundir los resultados
A13	Assertion T72 Speculated
R1	Speculation Arg1:T70 Arg2:T72	
T80	Observation 1987 1993	riesgo
A14	Assertion T80 Speculated
R2	Speculation Arg1:T70 Arg2:T80	
T81	Quantifier_or_Qualifier 110 114	dual
R3	Has_Quantifier_or_Qualifier Arg1:T2 Arg2:T81	
R4	Combined_with Arg1:T3 Arg2:T4	
R5	Used_for Arg1:T3 Arg2:T2	
R6	Has_Dose_or_Strength Arg1:T3 Arg2:T45	
R7	Has_Frequency Arg1:T3 Arg2:T46	
R8	Has_Dose_or_Strength Arg1:T4 Arg2:T47	
R9	Has_Frequency Arg1:T4 Arg2:T48	
R10	Experiences Arg1:T49 Arg2:T2	
R11	Experiences Arg1:T49 Arg2:T5	
R12	Causes Arg1:T58 Arg2:T5	
T83	Observation 215 241	virológicamente suprimidos
R13	Experiences Arg1:T49 Arg2:T83	
R15	Overlap Arg1:T83 Arg2:T6	
R16	Overlap Arg1:T83 Arg2:T7	
T86	Observation 278 294	impacto negativo
R17	Experiences Arg1:T49 Arg2:T6	
R18	Experiences Arg1:T49 Arg2:T7	
R19	Experiences Arg1:T49 Arg2:T86	
R20	Experiences Arg1:T49 Arg2:T8	
R21	Overlap Arg1:T83 Arg2:T8	
R22	Overlap Arg1:T83 Arg2:T86	
R23	Overlap Arg1:T83 Arg2:T9	
R24	Speculation Arg1:T51 Arg2:T9	
R25	Overlap Arg1:T32 Arg2:T52	
R26	Used_for Arg1:T31 Arg2:T32	
R27	Experiences Arg1:T49 Arg2:T9	
R28	Experiences Arg1:T49 Arg2:T32	
T88	Quantifier_or_Qualifier 438 449	controlados
R29	Has_Quantifier_or_Qualifier Arg1:T53 Arg2:T88	
R30	Experiences Arg1:T53 Arg2:T33	
T89	Observation 497 524	problemas en su tratamiento
R31	Experiences Arg1:T53 Arg2:T89	
R32	Overlap Arg1:T10 Arg2:T55	
R33	Causes Arg1:T10 Arg2:T89	
R34	Experiences Arg1:T53 Arg2:T10	
R35	Experiences Arg1:T56 Arg2:T11	
R36	Causes Arg1:T57 Arg2:T11	
T90	Observation 620 646	virológicamente suprimidos
R37	Experiences Arg1:T56 Arg2:T90	
R39	Before Arg1:T33 Arg2:T89	
R40	Experiences Arg1:T56 Arg2:T12	
R41	Experiences Arg1:T56 Arg2:T13	
R42	Experiences Arg1:T56 Arg2:T14	
R43	Experiences Arg1:T56 Arg2:T15	
R44	Experiences Arg1:T56 Arg2:T36	
R45	Overlap Arg1:T36 Arg2:T60	
R46	Speculation Arg1:T59 Arg2:T15	
R47	Causes Arg1:T35 Arg2:T15	
T91	Observation 684 700	impacto negativo
R48	Experiences Arg1:T56 Arg2:T91	
R49	Overlap Arg1:T90 Arg2:T12	
R50	Overlap Arg1:T90 Arg2:T13	
R51	Causes Arg1:T31 Arg2:T9	
R52	Causes Arg1:T35 Arg2:T13	
R53	Causes Arg1:T31 Arg2:T7	
R54	Overlap Arg1:T90 Arg2:T91	
R55	Overlap Arg1:T90 Arg2:T14	
R56	Overlap Arg1:T90 Arg2:T15	
R57	Used_for Arg1:T35 Arg2:T36	
R58	Before Arg1:T27 Arg2:T72	
R59	Before Arg1:T28 Arg2:T72	
R60	Before Arg1:T28 Arg2:T80	
R61	Before Arg1:T27 Arg2:T80	
R62	Experiences Arg1:T84 Arg2:T29	
R63	Experiences Arg1:T84 Arg2:T28	
R64	Experiences Arg1:T84 Arg2:T27	
R65	Experiences Arg1:T84 Arg2:T80	
R66	Has_Duration_or_Interval Arg1:T30 Arg2:T85	
R67	Has_Age Arg1:T62 Arg2:T64	
R68	Has_Age Arg1:T63 Arg2:T64	
R69	Has_Age Arg1:T61 Arg2:T64	
R70	Has_Age Arg1:T65 Arg2:T50	
R71	Negation Arg1:T66 Arg2:T87	
R72	Experiences Arg1:T65 Arg2:T16	
R73	Overlap Arg1:T16 Arg2:T67	
R74	Before Arg1:T16 Arg2:T17	
T92	DISO 1044 1071	seropositivos para el VIH-1
R75	Experiences Arg1:T68 Arg2:T92	
R76	Causes Arg1:T34 Arg2:T92	
#68	AnnotatorNotes T92	C2363741; HIV-1 infection; Disease or Syndrome
T94	Observation 1152 1166	inconvenientes
R78	Experiences Arg1:T69 Arg2:T94	
R79	Experiences Arg1:T69 Arg2:T19	
T95	Observation 1179 1195	impacto negativo
R80	Experiences Arg1:T69 Arg2:T95	
R81	Experiences Arg1:T69 Arg2:T20	
R82	Overlap Arg1:T38 Arg2:T73	
R83	Overlap Arg1:T37 Arg2:T38	
R84	Causes Arg1:T38 Arg2:T19	
R85	Causes Arg1:T35 Arg2:T12	
R86	Causes Arg1:T35 Arg2:T91	
R87	Causes Arg1:T31 Arg2:T86	
R88	Causes Arg1:T31 Arg2:T6	
R89	Speculation Arg1:T71 Arg2:T37	
R90	Causes Arg1:T38 Arg2:T95	
R91	Causes Arg1:T38 Arg2:T94	
R92	Experiences Arg1:T69 Arg2:T37	
R93	Experiences Arg1:T69 Arg2:T38	
T96	Observation 1294 1320	virológicamente suprimidos
R94	Experiences Arg1:T74 Arg2:T96	
R95	Has_Duration_or_Interval Arg1:T96 Arg2:T75	
T97	CONC 1359 1368	inclusión
#69	AnnotatorNotes T97	C1512693; Inclusion; Qualitative Concept
R96	Before Arg1:T96 Arg2:T97	
T98	Result_or_Value 1382 1397	<50 copias / mL
R97	Has_Result_or_Value Arg1:T39 Arg2:T98	
R98	Experiences Arg1:T74 Arg2:T39	
T99	Quantifier_or_Qualifier 1547 1558	planificado
R99	Has_Quantifier_or_Qualifier Arg1:T79 Arg2:T99	
T100	PROC 1581 1588	estudio
#70	AnnotatorNotes T100	C0681814; research study; Research Activity
R100	Overlap Arg1:T79 Arg2:T100	
R101	Overlap Arg1:T78 Arg2:T100	
R102	Overlap Arg1:T77 Arg2:T100	
T101	Observation 1593 1600	Fracaso
R103	Used_for Arg1:T23 Arg2:T40	
A15	Status T101 History_of
T102	Observation 1668 1675	Fracaso
A16	Status T102 History_of
R104	Used_for Arg1:T24 Arg2:T41	
R105	Used_for Arg1:T22 Arg2:T41	
R106	Before Arg1:T41 Arg2:T102	
R107	Before Arg1:T40 Arg2:T101	
R108	Experiences Arg1:T65 Arg2:T87	
T103	Observation 1462 1486	participar en el estudio
#71	AnnotatorNotes T103	C1278516; Patient participation status; Finding (?)
R109	Before Arg1:T21 Arg2:T103	
R112	Overlap Arg1:T5 Arg2:T8	
R123	Overlap Arg1:T5 Arg2:T9	
R115	Overlap Arg1:T11 Arg2:T14	
R125	Overlap Arg1:T11 Arg2:T12	
R126	Overlap Arg1:T11 Arg2:T13	
R127	Overlap Arg1:T11 Arg2:T15	
R113	Overlap Arg1:T5 Arg2:T7	
R117	Overlap Arg1:T5 Arg2:T6	
#72	AnnotatorNotes T99	C1301732; Planned; Functional Concept
#73	AnnotatorNotes T81	C1554184; Dual; Intellectual Product
#74	AnnotatorNotes T80	C0559571; At risk - finding; Finding
#75	AnnotatorNotes T83	C3888663; Sustained viral response; Finding (?)
#76	AnnotatorNotes T90	C3888663; Sustained viral response; Finding (?)
#77	AnnotatorNotes T96	C3888663; Sustained viral response; Finding (?)
#78	AnnotatorNotes T102	C0162643; treatment failure; Finding
#79	AnnotatorNotes T101	C0162643; treatment failure; Finding
#80	AnnotatorNotes T42	C5704646; Drug resistance mutation; Cell or Molecular Dysfunction
A17	Experiencer T69 Patient
A18	Experiencer T68 Patient
A19	Experiencer T74 Patient
A20	Experiencer T76 Patient
A21	Experiencer T65 Patient
A22	Experiencer T61 Patient
A23	Experiencer T62 Patient
A24	Experiencer T63 Patient
A25	Experiencer T56 Patient
A26	Experiencer T53 Patient
A27	Experiencer T49 Patient
A28	Experiencer T84 Patient
A29	Experiencer T82 Other
A30	Status T79 Future
T93	Result_or_Value 953 961	negativa
R14	Has_Result_or_Value Arg1:T16 Arg2:T93	
